Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Korea's Celltrion Deepens Cooperation With PPD For Entire Biosimilar Portfolio

This article was originally published in PharmAsia News

Executive Summary

SEOUL - South Korea's biosimilar front-runner Celltrion Inc. signed a memorandum of understanding with contract research organization Pharmaceutical Product Development Inc. to expand their ongoing cooperation in clinical trials to Celltrion's seven remaining biosimilars as well as its future biologic development projects

You may also be interested in...



Korea's Celltrion Sees Growth Trend Continue On Strength Of Biosimilar Validation Batch Orders

SEOUL - Celltrion, Inc. retained upward momentum in its earnings for the second quarter thanks to continued strong shipment of validation batches for biosimilars of Roche's breast cancer agent Herceptin (trastuzumab) and Johnson & Johnson's rheumatoid arthritis drug Remicade (infliximab)

Korea's Celltrion Sees Growth Trend Continue On Strength Of Biosimilar Validation Batch Orders

SEOUL - Celltrion, Inc. retained upward momentum in its earnings for the second quarter thanks to continued strong shipment of validation batches for biosimilars of Roche's breast cancer agent Herceptin (trastuzumab) and Johnson & Johnson's rheumatoid arthritis drug Remicade (infliximab)

Samsung Biologics Takes First Step In The CMO Business While Targeting Innovative Compounds By 2017

INCHEON, South Korea - Samsung Biologics entered the first stage of a plan to become a global biopharmaceutical company, breaking ground on a biologics manufacturing plant May 27. The company hopes to establish itself as a global contract manufacturer before entering the biosimilar sector with its first entrant, a biosimilar of the monoclonal antibody Rituxan (rituximab)

Related Content

UsernamePublicRestriction

Register

PS140995

Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel